Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Methenolone Market by Mode of Administration (Oral, Injectable) and by Application (Bodybuilding, Sports, Surgery, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03314

Pages: NA

Charts: NA

Tables: NA

Methenelone or methenelone enanthate is an injectable anabolic-androgenic steroid (AAS) belonging to the dihydrotestosterone (DHT) group. Methenolone is also known as primobolan. This drug is a single long acting ester steroid. It is one of the mildest anabolic steroids available in the market. Methenelone is low in androgen levels. This drug is used to promote weight gain following extensive surgery, severe trauma, chronic infection, and in other cases that result in inadequate weight gain or maintenance.

The popularity of this drug as a safe bulking alternative in bodybuilding augments the market growth. Furthermore, availability & application of this drug in surgical interventions are the key factors that propel the methadone market. However, rise in drug abuse related to methenolone and stringent government regulations towards this drug impede the growth of this market.

The global methadone market is segmented on the basis of mode of administration, application, and geography. Based on mode of administration, the market is bifurcated into oral and injectable mode of administration. On the basis of application, the market is divided into bodybuilding, sports, surgery, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Dragon Pharmaceuticals Inc., Wellona Pharma, Geneza Pharmaceuticals, Kosher Pharmaceuticals, British Dragon Pharmaceuticals, and International Pharmaceuticals, are provided in this report.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
  • Extensive analysis by product elucidates the use of methenelone in medical settings.

 Key Market Segments

  • By Mode of Administration
    • Oral
    • Injectable
  • By Application
    • Bodybuilding
    • Sports
    • Surgery
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Wellona Pharma
  • AKI Pharma
  • International Pharmaceuticals
  • British Dragon Pharmaceuticals
  • Actiza Pharmaceutical Private Limited
  • La Pharma Srl
  • Geneza Pharmaceuticals
  • Alpha-Pharma Healthcare
  • Kosher Pharmaceuticals
  • Dragon Pharmaceuticals Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: METHENOLONE MARKET, BY MODE OF ADMINISTRATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Mode Of Administration

    • 4.2. Oral

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Injectable

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: METHENOLONE MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Bodybuilding

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Sports

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Surgery

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: METHENOLONE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Mode Of Administration

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Methenolone Market

        • 6.2.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Methenolone Market

        • 6.2.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Methenolone Market

        • 6.2.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Mode Of Administration

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Methenolone Market

        • 6.3.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Methenolone Market

        • 6.3.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Methenolone Market

        • 6.3.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Methenolone Market

        • 6.3.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Methenolone Market

        • 6.3.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Methenolone Market

        • 6.3.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Methenolone Market

        • 6.3.11.1. Market Size and Forecast, By Mode Of Administration
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Mode Of Administration

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Methenolone Market

        • 6.4.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Methenolone Market

        • 6.4.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Methenolone Market

        • 6.4.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Methenolone Market

        • 6.4.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Methenolone Market

        • 6.4.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Methenolone Market

        • 6.4.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Methenolone Market

        • 6.4.11.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Methenolone Market

        • 6.4.12.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Methenolone Market

        • 6.4.13.1. Market Size and Forecast, By Mode Of Administration
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Mode Of Administration

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Methenolone Market

        • 6.5.5.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Methenolone Market

        • 6.5.6.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Methenolone Market

        • 6.5.7.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Methenolone Market

        • 6.5.8.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Methenolone Market

        • 6.5.9.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Methenolone Market

        • 6.5.10.1. Market Size and Forecast, By Mode Of Administration
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Dragon Pharmaceuticals Inc.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Wellona Pharma

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Geneza Pharmaceuticals

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Kosher Pharmaceuticals

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. British Dragon Pharmaceuticals

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. International Pharmaceuticals

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. AKI Pharma

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. La Pharma Srl

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Alpha-Pharma Healthcare

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Actiza Pharmaceutical Private Limited

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL METHENOLONE MARKET, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL METHENOLONE MARKET FOR ORAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL METHENOLONE MARKET FOR INJECTABLE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL METHENOLONE MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL METHENOLONE MARKET FOR BODYBUILDING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL METHENOLONE MARKET FOR SPORTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL METHENOLONE MARKET FOR SURGERY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL METHENOLONE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL METHENOLONE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA METHENOLONE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 13. U.S. METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 14. U.S. METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 15. CANADA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 16. CANADA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE METHENOLONE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. ITALY METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 27. ITALY METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. UK METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 31. UK METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC METHENOLONE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. CHINA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 40. CHINA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. INDIA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 44. INDIA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA METHENOLONE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. UAE METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 67. UAE METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA METHENOLONE, BY MODE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA METHENOLONE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. DRAGON PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 73. DRAGON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 74. DRAGON PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 75. DRAGON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 76. DRAGON PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. WELLONA PHARMA: KEY EXECUTIVES
  • TABLE 78. WELLONA PHARMA: COMPANY SNAPSHOT
  • TABLE 79. WELLONA PHARMA: OPERATING SEGMENTS
  • TABLE 80. WELLONA PHARMA: PRODUCT PORTFOLIO
  • TABLE 81. WELLONA PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. GENEZA PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 83. GENEZA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 84. GENEZA PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 85. GENEZA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 86. GENEZA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. KOSHER PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 88. KOSHER PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 89. KOSHER PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 90. KOSHER PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 91. KOSHER PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. BRITISH DRAGON PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 93. BRITISH DRAGON PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 94. BRITISH DRAGON PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 95. BRITISH DRAGON PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 96. BRITISH DRAGON PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. INTERNATIONAL PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 98. INTERNATIONAL PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 99. INTERNATIONAL PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 100. INTERNATIONAL PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 101. INTERNATIONAL PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. AKI PHARMA: KEY EXECUTIVES
  • TABLE 103. AKI PHARMA: COMPANY SNAPSHOT
  • TABLE 104. AKI PHARMA: OPERATING SEGMENTS
  • TABLE 105. AKI PHARMA: PRODUCT PORTFOLIO
  • TABLE 106. AKI PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. LA PHARMA SRL: KEY EXECUTIVES
  • TABLE 108. LA PHARMA SRL: COMPANY SNAPSHOT
  • TABLE 109. LA PHARMA SRL: OPERATING SEGMENTS
  • TABLE 110. LA PHARMA SRL: PRODUCT PORTFOLIO
  • TABLE 111. LA PHARMA SRL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. ALPHA-PHARMA HEALTHCARE: KEY EXECUTIVES
  • TABLE 113. ALPHA-PHARMA HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 114. ALPHA-PHARMA HEALTHCARE: OPERATING SEGMENTS
  • TABLE 115. ALPHA-PHARMA HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 116. ALPHA-PHARMA HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: KEY EXECUTIVES
  • TABLE 118. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: COMPANY SNAPSHOT
  • TABLE 119. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: OPERATING SEGMENTS
  • TABLE 120. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: PRODUCT PORTFOLIO
  • TABLE 121. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL METHENOLONE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL METHENOLONE MARKET
  • FIGURE 3. SEGMENTATION METHENOLONE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN METHENOLONE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALMETHENOLONE MARKET
  • FIGURE 11. METHENOLONE MARKET SEGMENTATION, BY BY MODE OF ADMINISTRATION
  • FIGURE 12. METHENOLONE MARKET FOR ORAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. METHENOLONE MARKET FOR INJECTABLE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. METHENOLONE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. METHENOLONE MARKET FOR BODYBUILDING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. METHENOLONE MARKET FOR SPORTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. METHENOLONE MARKET FOR SURGERY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. METHENOLONE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: METHENOLONE MARKET
  • FIGURE 25. TOP PLAYER POSITIONING, 2024
  • FIGURE 26. DRAGON PHARMACEUTICALS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 27. DRAGON PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 28. DRAGON PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 29. WELLONA PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. WELLONA PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. WELLONA PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. GENEZA PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. GENEZA PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. GENEZA PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. KOSHER PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. KOSHER PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. KOSHER PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. BRITISH DRAGON PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. BRITISH DRAGON PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. BRITISH DRAGON PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. INTERNATIONAL PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. INTERNATIONAL PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. INTERNATIONAL PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. AKI PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. AKI PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. AKI PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. LA PHARMA SRL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. LA PHARMA SRL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. LA PHARMA SRL: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. ALPHA-PHARMA HEALTHCARE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. ALPHA-PHARMA HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. ALPHA-PHARMA HEALTHCARE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Methenolone Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved